PCSK9 inhibitor (non-antibody)
PCSK9 inhibitor, non-antibody (peptide / binding protein)
- Binds circulating PCSK9 at the surface it uses to grip the LDL receptor, so the receptor escapes degradation and keeps clearing LDL
- One mechanism, two formats: a macrocyclic peptide small enough to swallow, and an albumin-fused binding protein given monthly
- Binds circulating PCSK9 at the surface it uses to grip the LDL receptor, so the receptor escapes degradation and keeps clearing LDL
- One mechanism, two formats: a macrocyclic peptide small enough to swallow, and an albumin-fused binding protein given monthly
Drugs with this mechanism (2)
- Enlicitide — First oral PCSK9 inhibitor; injection-free LDL lowering for patients still above goal on statins.
- Lerodalcibep — PCSK9-binding fusion protein for hypercholesterolemia, including heterozygous familial disease.
All mechanisms · Open PCSK9 inhibitor (non-antibody) in the interactive console ↗